Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$12.00 target price on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) in a Sept. 2 update after the company reported one-year data from its ongoing RESOLVE trial in eosinophilic esophagitis. Victoria-based Eupraxia is a drug delivery company developing its lead […]
Research Capital analyst Andre Uddin lowered his target price for NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN) to $7.70 from $12.00 in an Aug. 26 report while maintaining a “Speculative Buy” rating, citing a more conservative valuation approach despite continued optimism about its lead drug candidate. Vancouver-based NervGen is developing NVG-291, […]
Share
Tweet
Share
